Diurnal Limited (DNL LN)

Diurnal Limited engages in the research and development of products to deliver therapeutics to humans in the United Kingdom. The company targets patient needs in chronic endocrine (hormonal) diseases. Its product pipeline includes Infacort that is in Phase III clinical trial for use in the control of Adrenal Insufficiency in neonates, infants, small children, pre-pubescent children; and Chronocort, a cortisol replacement product, which is in Phase III clinical trial for the life-long treatment of congenital adrenal insufficiency and adrenal insufficiency. The company also develops native testosterone formulation for hypogonadism; and TRI4COMBI for hypothyroidism. Diurnal Limited was incorporated in 2015 and is based in Cardiff, the United Kingdom.